Opexa Therapeutics, Inc. Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares …

THE WOODLANDS, Texas--(BUSINESS WIRE)--

Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 650,000 shares of its common stock, at a price to the public of $1.50 per share, in connection with the Companys recently announced underwritten public offering of 12,000,000 shares of common stock, bringing total gross proceeds from the offering to $18,975,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Aegis Capital Corp. acted as sole book-running manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 7, 2013. The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering are available on the SECs website at http://www.sec.gov. Copies of the prospectus may also be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18thFloor, New York, NY, 10019, via telephone at (212) 813-1010, or via email at prospectus@aegiscap.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Opexa

Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.

See original here:
Opexa Therapeutics, Inc. Announces Closing of Partial Exercise of Underwriters’ Option to Purchase Additional Shares ...